Product Description
Eflornithine administered by injection is used to treat African sleeping sickness, a disease caused by protozoa (tiny one-celled animals). However, eflornithine hydrochloride applied topically as a cream is the first agent known to help slow the rate of excessive hair growth. It is marketed under the brand name Vaniqa® and comes as eflornithine hydrochloride 13.9% cream. Eflornithine works by blocking the enzyme ornithine decarboxylase (ODC) that stimulates hair growth. (Sourced from: https://dermnetnz.org/topics/eflornithine-hydrochloride)
Mechanisms of Action: ODC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Cancer Prevention
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Honduras, Puerto Rico, United States
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Astrocytoma
Phase 2: Brain Cancer|Carcinogenesis|Gastrointestinal Cancer|Glioma|Neuroblastoma|Osteosarcoma|Rhabdoid Tumor|Sarcoma, Ewing|Type 1 Diabetes
Phase 1: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BCC020 | P2 |
Not yet recruiting |
Osteosarcoma|Sarcoma, Ewing|Brain Cancer|Glioma|Neuroblastoma|Rhabdoid Tumor |
2032-12-01 |
|
| TADPOL | P2 |
Recruiting |
Type 1 Diabetes |
2027-12-01 |
|
| OT-21-101 | P1 |
Recruiting |
Glioblastoma |
2024-12-15 |
44% |
| STELLAR Study | P3 |
Active, not recruiting |
Astrocytoma |
2024-03-12 |